Fetal bovine serum (FBS) is used for MSC preparation in pre-clinical animal models and veterinary applications, recently in US clinical trials, and for MSC products with current foreign market authorizations. The effect of anti-bovine titers, which are common in animals and humans, has not been investigated. In the equine model, where anti-bovine titers are universally high due to routine vaccination, we evaluated the recipient immune response to autologous MSCs prepared with and without FBS. Preparation of MSCs with FBS resulted in post injection inflammation and antibody mediated cytotoxicity of MSCs when compared to MSCs prepared without FBS. Importantly, synovial MSC concentrations were reduced and LPS induced pain was higher, when FBS was used to prepare MSCs, demonstrating reduced efficacy of FBS prepared MSCs. Fetal bovine serum should no longer be utilized for MSC preparation in pre-clinical study, clinical study, or veterinary applications. The use of FBS in previously reported studies, and in MSC therapeutics with current foreign market authorization, should be considered when interpreting results.

胎牛血清 (FBS) 用于临床前动物模型和兽医应用中的 MSC 制备，最近在美国临床试验中，以及用于目前获得国外市场授权的 MSC 产品。尚未研究动物和人类中常见的抗牛滴度的影响。在马模型中，由于常规疫苗接种，抗牛滴度普遍较高，我们评估了受体对使用和不使用 FBS 制备的自体 MSC 的免疫反应。与不使用 FBS 制备的 MSC 相比，使用 FBS 制备 MSC 会导致注射后炎症和抗体介导的 MSC 细胞毒性。重要的是，当使用 FBS 制备 MSC 时，滑膜 MSC 浓度降低且 LPS 引起的疼痛更高，这表明 FBS 制备的 MSC 的功效降低。胎牛血清不应再用于临床前研究、临床研究或兽医应用中的 MSC 制备。在解释结果时，应考虑在先前报告的研究中使用 FBS，以及在目前获得国外市场授权的 MSC 疗法中使用 FBS。